Company Overview and News

1
Relentless Resources Announces Acquisition of Late Stage ACMPR Applicant, Record Date of Rights Offering, Fully Funded Phase 1 Cannabis Cultivation Facility, Additions to Its Team, and Proposed Name Change

2018-06-01 globenewswire
CALGARY, Alberta, May 31, 2018 (GLOBE NEWSWIRE) -- Relentless Resources Ltd. (“Relentless” or the “Company”) (TSX-V:RRL) is pleased to announce that it has entered into an amalgamation agreement dated May 31, 2018 (the “Amalgamation Agreement”) with Grunewahl Organics Inc. (“Grunewahl”) and Relentless’ wholly-owned subsidiary, 2114152 Alberta Ltd. (“AcquisitionCo”), to acquire all of the issued and outstanding shares of Grunewahl (the “Transaction”).
IMO RRL IMO

1
Move over Waterloo and Ottawa, Calgary is now out-innovating you

2018-05-31 cbc.ca
You might be surprised to know that Calgary has now taken the lead on that front, as measured by one of the most common ways of gauging innovation — patents.
IMO IMO

18
Alberta Pipeline Disrupted as Fire Season Starts in Oil Patch - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CVE IMO CNQ CVE IMO IPPLF IPL SU SU

1
Toronto’s lost architectural history returns to downtown with new Campbell House Museum exhibit

2018-05-11 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
IMO IMO

11
Oilpatch CEOs blame high costs, red tape for erosion of Canada's competitive edge

2018-05-07 cbc.ca
CEOs of the largest oilpatch companies are stepping up to the podium this month for their annual address to shareholders and, one by one, they are painting a picture of how uncompetitive it is to operate in Canada and attract investment dollars.
IMO CNQ IMO

1
Air and water quality reforms needed to curb toxic emissions, opposition parties say

2018-05-04 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
IMO IMO

2
Pollution from Canadian refineries an ‘embarrassment’ compared with U.S.

2018-05-02 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
IMO IMO MPC

1
Park set to open in once-contaminated Lynnview Ridge in southeast Calgary

2018-05-01 cbc.ca
The once-contaminated Lynnview Ridge district in southeast Calgary is set to reopen this spring as a new greenspace.
IMO IMO

8
Oilpatch eager to ship more oil by rail as pipeline capacity at limit

2018-05-01 cbc.ca
With no capacity to spare on pipelines out of Alberta, oilpatch leaders are desperately waiting for when they'll be able to ship more crude on rail lines.
HSE IMO KMI.PRA KMI KMI.WS HUSKF KMR IMO KMRFZ CVB

1
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of April 30

2018-04-29 seekingalpha
It will be one of the busiest weeks of the year as there are 25 Canadian Dividend All-Stars scheduled to report earnings this coming week. Of those, there are a couple of potential raise announcements, but only one should be considered a lock. Before we look ahead, let’s digest last week’s results.
LBLCF IMO L CPXGF IMO

8
Imperial Oil Hikes Dividend, Buyback After Profit Jump

2018-04-27 rigzone
April 27 (Reuters) - Canada's Imperial Oil Ltd on Friday reported a 55 percent jump in quarterly profit, helped by strength in its refining and chemicals businesses, and the company boosted its dividend and repurchase program.
HSE IMO XOM HUSKF IMO

19
CANADA STOCKS-TSX edges higher, led by financials

2018-04-27 reuters
April 27 (Reuters) - Canada’s main stock index climbed higher, led by financials, amid optimism of peace between both Koreas and expectations of a final NAFTA deal.
IMO WJA TXCX HUSKF DRGDF IMO WJAFF AC HSE ACDVF DGC AEM BTE

7
Imperial Oil's profit jumps on refining, chemicals strength

2018-04-27 channelnewsasia
REUTERS: Canada's Imperial Oil Ltd reported a 55 percent rise in quarterly profit, as its refining and chemicals businesses benefited from cheaper raw materials, offsetting discounted Canadian crude prices.
IMO XOM IMO

1
Imperial Oil boosts dividend after increase in Q1 profit

2018-04-27 cbc.ca
Imperial Oil Ltd. raised its dividend as it reported its first-quarter profit improved compared with a year ago.
IMO IMO

7
Canada's Imperial Oil reports 55 percent rise in profit - Channel NewsAsia

2018-04-27 channelnewsasia
REUTERS: Canada's oil producer and refiner Imperial Oil Ltd reported a 55 percent rise in quarterly profit, as strength in its refining and chemicals businesses offset discounted Canadian crude prices.
IMO XOM IMO

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to TSX:IMO / Imperial Oil on message board site Silicon Investor.

Silicon Motion Inc. (SIMO) SIMO Busters
Simon Property Group, Inc. (SPG) Imogo Mobile Technologies Corp.
PIMO, any thoughts on the stock movements? Timothy McVeigh
PIMO Recently Signed another Auto-DR Contract PIMO has one of the most impressive BOD���s for a micro cap
PIMO Provides Shareholder Update PIMO Energy Division Secures Another Contract